Ipca Laboratories (IPCALAB) Share Price Rises 3.74% to Rs 1,882.95

Ipca Laboratories Share Price moved higher today, with the stock last traded at Rs 1,882.95, up 3.74% from the previous close of Rs 1,815.10. According to Univest data, the market capitalisation stood at Rs 46,049.85 crore, placing Ipca Laboratories Share Price among the larger names in the Healthcare space on an absolute market-cap basis. The intraday path was clean: the stock opened at Rs 1,791.80, touched a low of Rs 1,791.80 and reached a high of Rs 1,882.95, which also matched the latest trade shown here. This is a clear share price rise, but no company-specific catalyst is established. In other words, the price event is confirmed, and the numbers are real, while the reason remains unverified. For readers tracking Ipca Laboratories Stock News, the main point today is the strength in price action and the valuation context that follows in the next sections of this Ipca Laboratories Share Price analysis.

Ipca Laboratories Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,882.95
Previous Close	Rs 1,815.1
Today's Move	Rs 67.85 (+3.74%)
Open	Rs 1,791.8
High	Rs 1,882.95
Low	Rs 1,791.8
Market Capitalisation	Rs 46,049.85 crore
Market Cap Category	Large Cap

Ipca Laboratories Ltd. (IPCALAB) rose to Rs 1,882.95 from the previous close of Rs 1,815.1, a move of Rs 67.85 or 3.74%. The stock opened at Rs 1,791.8, reached a high of Rs 1,882.95, recorded a low of Rs 1,791.8.

Ipca Laboratories Share Price is trading higher today, with the stock up Rs 67.85 over the previous close and the entire move captured within the day’s range. The opening price was Rs 1,791.80, the low was Rs 1,791.80 and the high was Rs 1,882.95, which means the latest trade is at the upper end of the intraday range. That makes today’s price action straightforward to read: the stock started below the previous close, moved higher through the session and was last seen at the day’s peak. For anyone following Ipca Laboratories Share Price Today, the move matters because it gives a clean snapshot of intraday strength without adding any unverified explanation. This is the kind of share price update that keeps Ipca Laboratories Stock News in focus. The next layer is the company’s fundamental profile, which helps place this share price rise in context.

Ipca Laboratories Ltd. (IPCALAB) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 46,049.85 crore
P/E Ratio	35.16x
P/B Ratio	5.43x
ROE	15.88%
ROCE	19.41%
EPS	Rs 51.63
Book Value Per Share	Rs 334.38
Dividend Yield	0.33%

Ipca Laboratories Ltd. (IPCALAB) fundamental metrics show P/E 35.16x, P/B 5.43x, ROE 15.88%, ROCE 19.41%. These ratios show where the company stands today and are not a call to buy or sell.

Ipca Laboratories Ltd. has a market capitalisation of Rs 46,049.85 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 35.16x, P/B at 5.43x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 15.88% and ROCE of 19.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 51.63, book value per share of Rs 334.38, dividend yield of 0.33%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.73x, median ROE of 11.33%, median ROCE of 13.25%. Together they describe the fundamental backdrop without implying a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	35.16x
Benchmark Median P/E	31.73x
Benchmark Average P/E	45.98x
Benchmark P/E Range	3.1x to 616.89x
Company P/B Ratio	5.43x
Benchmark Median P/B	2.76x
Company ROE	15.88%
Benchmark Median ROE	11.33%
Company ROCE	19.41%
Benchmark Median ROCE	13.25%
Company Market Capitalisation	Rs 46,049.85 crore
Benchmark Median Market Cap	Rs 771.43 crore

Ipca Laboratories Ltd. (IPCALAB) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Ipca Laboratories Ltd. (IPCALAB) has a P/E ratio of 35.16x, which is above the benchmark median of 31.73x, a difference of +10.81%. A P/E difference of this kind is a reference point rather than a recommendation.

Ipca Laboratories Ltd. (IPCALAB) has a ROE of 15.88%, which is above the benchmark median of 11.33%, a difference of +40.16%. Ipca Laboratories Ltd. (IPCALAB) has a ROCE of 19.41%, which is above the benchmark median of 13.25%, a difference of +46.49%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries Ltd.	SUNPHARMA	4,18,683.95	34.61	4.84	14.85	19.11
Divi's Laboratories Ltd.	DIVISLAB	2,41,310.94	82.5	13.66	16.19	21.51
Torrent Pharmaceuticals Ltd.	TORNTPHARM	1,73,078.79	79.36	19.28	26.76	19.27
Laurus Labs Ltd.	LAURUSLABS	1,11,433.99	101.92	19.76	18.31	18.2
Zydus Lifesciences Ltd.	ZYDUSLIFE	1,11,022.18	24.6	4.12	19.69	21.39

Ipca Laboratories Ltd. (IPCALAB) has a P/E ratio of 35.16x compared with the displayed peer median of 79.36x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 15.88% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 19.41% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Ipca Laboratories Ltd. (IPCALAB) has a market capitalisation of Rs 46,049.85 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Ipca Laboratories

• Ipca Laboratories Share Price is up 3.74% today, with the stock last traded at Rs 1,882.95 and the intraday high matching that level.
• The company’s P/E of 35.16 and P/B of 5.43 give Ipca Laboratories Share Price a valuation profile that is above the industry median.
• ROE of 15.88% and ROCE of 19.41% add return context to the latest Ipca Laboratories Share Price move.
• Market capitalisation of Rs 46,049.85 crore keeps Ipca Laboratories Share Price relevant within healthcare market updates.
• Peers such as Sun Pharma, Zydus Lifesciences and Cipla provide a clear comparison set for Ipca Laboratories Share Price.

About Ipca Laboratories

Ipca Laboratories Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is known for pharmaceuticals-focused business activity, and the market tracks it through price, earnings and valuation metrics that are standard for the sector. For Ipca Laboratories Share Price readers, the most relevant operating context today is that the company is valued as a sizeable listed healthcare business with a market capitalisation of Rs 46,049.85 crore. The latest Univest figures show a P/E of 35.16, P/B of 5.43, ROE of 15.88%, ROCE of 19.41%, EPS of Rs 51.63, book value of Rs 334.38 and dividend yield of 0.33%. Those metrics help frame the stock’s company overview, financial analysis and market cap positioning. In practical terms, Ipca Laboratories Share Price reflects both the company’s earnings base and how the market is currently valuing that base within the pharmaceutical universe.

Frequently Asked Questions

What is Ipca Laboratories Share Price today?

Ans. Ipca Laboratories Share Price was last traded at Rs 1,882.95, up 3.74% from the previous close of Rs 1,815.10. The latest trade also matched the day’s high. The intraday range extended from Rs 1,791.8 to Rs 1,882.95.

Why is Ipca Laboratories Share Price rising today?

Ans. The price move is confirmed in Univest data; a company-specific reason has not been established. The stock is higher by Rs 67.85 today, with the move fully visible in intraday price action.

What is the market capitalisation of Ipca Laboratories?

Ans. Ipca Laboratories has a market capitalisation of Rs 46,049.85 crore. That scale is much larger than the industry median in the same industry benchmark and helps frame the stock’s valuation context.

How does Ipca Laboratories Share Price compare with peers?

Ans. Ipca Laboratories Share Price has a lower market cap than Sun Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Laurus Labs and Zydus Lifesciences, but its valuation and return ratios remain competitive within the listed peer set.

What are the key valuation metrics for Ipca Laboratories Share Price?

Ans. The latest Univest figures show a P/E of 35.16 and a P/B of 5.43. Those readings sit above the industry medians, so the stock is not trading at a low valuation versus its benchmark set.

What do ROE and ROCE show for Ipca Laboratories?

Ans. ROE stands at 15.88% and ROCE at 19.41%. Both ratios are above the industry medians, which gives Ipca Laboratories Share Price some fundamental support within the Healthcare sector.

What is the EPS and book value of Ipca Laboratories?

Ans. EPS is Rs 51.63 and book value is Rs 334.38. EPS reflects earnings attributable to each share, while book value shows the accounting net worth behind each share.

Does Ipca Laboratories pay a dividend?

Ans. Yes, the dividend yield is 0.33%. That is a historical payout measure, so it should be read alongside the current price, valuation and earnings profile rather than in isolation.

Track Ipca Laboratories Share Price on Univest

Use Ipca Laboratories Ltd. (IPCALAB) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Investors tracking Ipca Laboratories Share Price can use Univest to follow live price movement, market capitalisation, valuation ratios, 52-week levels and broader market insights in one place. The same page also helps readers compare Ipca Laboratories Share Price Today with sector peers, review the latest financial ratios and keep an eye on stock performance as new market data comes in. If you are following Ipca Laboratories Stock News, Univest offers a compact way to review the share price rise, fundamental analysis and sector context together. That makes it easier to read Price Action alongside company financials without losing the bigger picture.